Showing 4011-4020 of 8129 results for "".
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- Triple-Combo Gel Reduces Acne Lesions, Scarring, and PIH Over 6 Months: Studyhttps://practicaldermatology.com/news/study-triple-combo-gel-reduces-acne-lesions-scarring-and-pih-over-6-months/2474438/Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) was associated with significant long-term efficacy and safety in the treatment of moderate acne and associated sequelae, results from a new 24-week open-label study indicate.
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- Study: Laser Therapy Shows Success in HS Management for Skin of Colorhttps://practicaldermatology.com/news/new-study-highlights-laser-therapy-success-in-hs-management-for-skin-of-color/2474344/Fractional ablative CO₂ laser therapy (AFCL) significantly improved hidradenitis suppurativa (HS) outcomes among patients with skin of color, according to a new retrospective study presented at the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk